Ibrutinib for Chronic Lymphocytic Leukemia

被引：0
|
作者：
Sharman, Jeff P. [1 ]
Mato, Anthony R. [2 ]
Keating, Michael J. [3 ]
机构：
[1] Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2016年 / 374卷 / 16期
关键词：
PREVIOUSLY UNTREATED PATIENTS; CHLORAMBUCIL; THERAPY;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1592 / 1593
页数：2
相关论文
共 50 条
  • [21] Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Brown, J. R.
    Eichhorst, B.
    Hillmen, P.
    Jurczak, W.
    Kazmierczak, M.
    Lamanna, N.
    O'Brien, S. M.
    Tam, C. S.
    Qiu, L.
    Zhou, K.
    Simkovic, M.
    Mayer, J.
    Gillespie-Twardy, A.
    Ferrajoli, A.
    Ganly, P. S.
    Weinkove, R.
    Grosicki, S.
    Mital, A.
    Robak, T.
    Osterborg, A.
    Yimer, H. A.
    Salmi, T.
    Wang, M. -D. -Y.
    Fu, L.
    Li, J.
    Wu, K.
    Cohen, A.
    Shadman, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (04): : 319 - 332
  • [22] Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
    Roeker, Lindsey E.
    Yazdy, Maryam Sarraf
    Rhodes, Joanna
    Goodfriend, Julie
    Narkhede, Mayur
    Carver, Joseph
    Mato, Anthony
    JAMA NETWORK OPEN, 2019, 2 (12) : E1916326
  • [23] Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib
    Sittig, Katherine R.
    Laageide, Leah G.
    Akhtar, Zaheer
    Wall, Geoffrey C.
    Kumar, Sudhir C.
    IDCASES, 2021, 24
  • [24] Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on
    Molica, Stefano
    Matutes, Estella
    Tam, Constantine
    Polliack, Aaron
    HEMATOLOGICAL ONCOLOGY, 2020, 38 (02) : 129 - 136
  • [25] Overcoming Ibrutinib Resitance In Relapsed Chronic Lymphocytic Leukemia
    Sharma, Kamal
    Stuart, August
    Epner, Elliot M.
    Loughran, Thomas P., Jr.
    BLOOD, 2013, 122 (21)
  • [26] Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
    Shanafelt, T. D.
    Wang, X. V.
    Kay, N. E.
    Hanson, C. A.
    O'Brien, S.
    Barrientos, J.
    Jelinek, D. F.
    Braggio, E.
    Leis, J. F.
    Zhang, C. C.
    Coutre, S. E.
    Barr, P. M.
    Cashen, A. F.
    Mato, A. R.
    Singh, A. K.
    Mullane, M. P.
    Little, R. F.
    Erba, H.
    Stone, R. M.
    Litzow, M.
    Tallman, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (05): : 432 - 443
  • [27] Role of Ibrutinib Based Regimen in Chronic Lymphocytic Leukemia
    Sardar, Muhammad
    Malik, Saad Ullah
    Khan, Ali Younas
    Sohail, Chaudhry Saad
    Ahmad, Malik Qistas
    Amin, Saher Nasir
    Chakraborty, Rajshekar
    McBride, Ali
    Azharuddin, Muhammad
    Sharon, David
    Lee, Patrick
    Faridi, Warda
    Anwer, Faiz
    BLOOD, 2018, 132
  • [28] Integrated analysis of ibrutinib resistance in chronic lymphocytic leukemia
    Ahn, Inhye E.
    Albitar, Adam
    Underbayev, Chingiz
    Herman, Sarah
    Tian, Xin
    Soto, Susan
    Stetler-Stevenson, Maryalice
    Maric, Irina
    Farooqui, Mohammed Z.
    Albitar, Maher
    Wiestner, Adrian
    CANCER RESEARCH, 2016, 76
  • [29] Combination of ibrutinib with immunochemotherapy in patients with chronic lymphocytic leukemia
    Tomowiak, Cecile
    Leleu, Xavier
    HEMATOLOGIE, 2015, 21 (04): : 206 - 207
  • [30] Acalabrutinib versus ibrutinib in relapsed chronic lymphocytic leukemia
    Stocker, Nicolas
    HEMATOLOGIE, 2021, 27 (06): : 259 - 260
12345